Know Cancer

forgot password

Correlation of [D10] Phenanthrene Metabolism With Bronchoepitheial Dysplasia and Metaplasia in Smokers at High Risk for Lung Cancer

18 Years
Open (Enrolling)
Lung Cancer, Squamous Lung Dysplasia, Tobacco Use Disorder

Thank you

Trial Information

Correlation of [D10] Phenanthrene Metabolism With Bronchoepitheial Dysplasia and Metaplasia in Smokers at High Risk for Lung Cancer


I. To determine the relationship between urinary deuterated ([D10]) phenanthrene tetraol
(PheT) level, PheT:phenanthrols (HOPhe) ratio, and the presence of bronchoepithelial
metaplasia and/or dysplasia in smokers who have undergone screening bronchoscopy at Roswell
Park Cancer Institute (RPCI).


Patients receive deuterated phenanthrene tetraol orally (PO). Urine samples are collected
for laboratory studies for 6 hours after dosing.

Inclusion Criteria:

- Enrolled in the High Risk Lung Cancer (HRLC) Screening Program

- Eligible for bronchoscopy or have undergone screening bronchoscopy in the past

- Current smoker of at least 10 cigarettes daily

- Able to provide written consent indicating an understanding of the investigational
nature of the study

- Willing to take [D10]phenanthrene in water with 20% ethanol

Exclusion Criteria:

- Previous aerodigestive tract cancer

- Currently attempting to cut down or quit smoking

- Major medical co-morbidities, for example, renal dysfunction, heart failure, and
diabetes, to be adjudicated by study physicians

- Pregnant women, women intending to become pregnant, or women who are breastfeeding

- Former or recovering alcoholics

- Those needing to take medications such as metronidazole, chlorpromazine, Antabuse or
benzodiazepines within 7 days of the deuterated phenanthrene dosing, as they could
potentially interact with ethanol; ineligibility based on use of other medications is
at the discretion of the study physicians

Type of Study:


Study Design:

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Outcome Measure:

Urinary deuterated phenanthrene tetraol level

Outcome Description:

A multiple regression analysis will be performed including explanatory variables such as lesion status, presence/absence of chronic obstructive pulmonary disease (COPD) or asbestos, duration of smoking, smoking intensity, age, and gender.

Outcome Time Frame:

Up to 6 hours

Safety Issue:


Principal Investigator

Alex Adjei

Investigator Role:

Principal Investigator

Investigator Affiliation:

Roswell Park Cancer Institute


United States: Institutional Review Board

Study ID:

I 194611



Start Date:

July 2012

Completion Date:

Related Keywords:

  • Lung Cancer
  • Squamous Lung Dysplasia
  • Tobacco Use Disorder
  • Lung Neoplasms
  • Tobacco Use Disorder



Roswell Park Cancer InstituteBuffalo, New York  14263